Scientific Publications

News

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL; T-ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 is a CD7-targeting, allogeneic, fratricide-resistant […]

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia

Science Translational Medicine, Berrien-Elliot et al, February 2022

Memory-like differentiation enhances NK cell responses to melanoma

Clin Cancer Res, Marin et al, June 2021

Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Cancer Discovery, Berrien-Elliott et al, December 2020

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Blood, Gang et al, November 2020

Memory-like natural killer cells for cancer immunotherapy

Seminars in Hematology, Gang et al, November 2020

Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies

Best Practice & Research Clinical Haematology, Cooper and DiPersio, December 2019

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

Leukemia, Cooper et al, February 2018

Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcγRIIIa-Triggered Responses

Biol Blood Marrow Transplant, Wagner et al, March 2017

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Science Translational Medicine, Romee et al, September 2016

Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Biol Blood Marrow Transplant, Leong et al, April 2014

Cytokine activation induces human memory-like NK cells.

Blood, Romee et al, December 2012

Latest News

Allotera Therapeutics Announces Opening of Minimal Residual Disease Cohort in the Pivotal T-RRex Study of Sofi-cel

The minimal residual disease-positive cohort opens as part of the pivotal-stage development of Soficabtagene Geleucel …

Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers

Additional capital brings total raised to $150 million in a Series C financing Funds support …

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL; T-ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 …